Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia | MicrobiomeTrials← Back to trialsNCT07721480
Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2028-12
Enrollment target: 6 participants Other microbiome trials you might be interested in
Transfusion-dependent Beta-Thalassemia
This is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial in…
Rome, ItalyEst. completion Oct 2028
Thalassemia IntermediaThalassemia MajorGrowth DelayPuberty, Delayed
There are nearly 300,000 patients with severe or intermediate thalassemia in China. Growth retardation is the most signi…
Tianjin, ChinaEst. completion Oct 31, 2026